Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 1/20 | 0.71 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.59 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.59 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.55 |
| ▸ | KIF11 | P52732 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 2/20 | 0.51 |
| ▸ | MMP3 | P08254 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | MMP14 | P50281 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | MMP1 | P03956 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.50 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.50 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4205144 | 0.90 | PGR (0.85) | PGRFFAR1KIF11PTPN1LMNA | |
| SCHEMBL644458 | 0.88 | KEAP1 (0.60) | PGRKIF11LMNAMAPK1NR3C2 | |
| SCHEMBL3116450 | 0.83 | PGR (0.73) | PGRKIF11LMNAGAAMAPK1 | |
| SCHEMBL28015271 | 0.83 | PGR (1.00) | PGRFFAR1FFAR4GAANPC1 | |
| SCHEMBL3112491 | 0.83 | PGR (0.73) | PGRFFAR1KIF11PTPN1LMNA | |
| SCHEMBL4659812 | 0.82 | KIF11 (0.66) | KIF11LMNANR3C2HPGDSMN1; SMN2 | |
| SCHEMBL2451476 | 0.81 | PGR (0.71) | PGRFFAR1KIF11PTPN1LMNA | |
| SCHEMBL3111013 | 0.81 | KIF11 (0.73) | PGRKIF11PTPN1LMNAGAA | |
| SCHEMBL3107843 | 0.81 | KIF11 (0.82) | PGRKIF11PTPN1LMNAGAA | |
| SCHEMBL3376915 | 0.79 | PGR (0.90) | PGRFFAR1FFAR4KIF11NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | VERNALIS (R&D) LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | CNR1, OPRL1, CHRNA10 | PGR 730/4885FFAR1 380/4885FFAR4 820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.